[Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and aethinyloestradiol women with virilising symptoms (author's transl)].

The study involved 167 women treated with 2 mg Cyproteronacetate and 50 µg Ethinyloestradiol for acne, seborrhoea, hirsutism, and androgenetic alopecia over 12 months. Treatment success varied with the severity of symptoms: 77% improvement in mild acne cases and 91.4% in severe cases; seborrhoea improved in 55.7% of mild and 89.4% of severe cases; hirsutism improved in 37.4% of mild and 60.9% of severe cases. Acne showed significant improvement after 6 months, while seborrhoea and hirsutism improved up to 10 months. Side effects included spotting (17.1%), breakthrough bleeding (6%), breast tension (16.2%), and nervousness (68.7%). The dropout rate was 7.8%, comparable to other oral contraceptives.